Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to $20.3 million.

  • Kiniksa Pharmaceuticals International's Cost of Revenue rose 73.6% to $20.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.6 million, marking a year-over-year increase of 4187.61%. This contributed to the annual value of $60.9 million for FY2024, which is 8232.71% up from last year.
  • Per Kiniksa Pharmaceuticals International's latest filing, its Cost of Revenue stood at $20.3 million for Q3 2025, which was up 73.6% from $18.6 million recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Cost of Revenue peaked at $20.3 million during Q3 2025, and registered a low of $491000.0 during Q1 2023.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's median Cost of Revenue value was $8.4 million (recorded in 2023), while the average stood at $9.8 million.
  • As far as peak fluctuations go, Kiniksa Pharmaceuticals International's Cost of Revenue plummeted by 8836.22% in 2023, and later surged by 205539.71% in 2024.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Cost of Revenue stood at $3.9 million in 2021, then soared by 73.52% to $6.7 million in 2022, then surged by 42.83% to $9.6 million in 2023, then skyrocketed by 86.73% to $17.9 million in 2024, then rose by 13.19% to $20.3 million in 2025.
  • Its Cost of Revenue stands at $20.3 million for Q3 2025, versus $18.6 million for Q2 2025 and $17.9 million for Q1 2025.